Analyst consensus rating
Insight Molecular Diagnostics Analyst Rating: Buy
IMDX is rated Buy by 4 analysts with a $8.25 target. As of 2026-08-31.
Direct answer
Insight Molecular Diagnostics's consensus rating is Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.25.
Forecast evidence checked August 31, 2026.
Get free Insight Molecular Diagnostics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.13
- Average price target
- $8.25
- High price target
- $12.00
- Low price target
- $4.00
- Low target gap
- -3.1%
- Target upside
- +99.8%
- High target gap
- +190.6%
- Target range width
- 193.7%
- Consensus rating
- Buy
- Analysts
- 4
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Insight Molecular Diagnostics?
Insight Molecular Diagnostics has a verified Buy consensus. The same dataset has an average price target of $8.25.
How far are Insight Molecular Diagnostics's low and high targets from the recorded price?
The low target implies -3.1%, while the high target implies +190.6%.
How many analysts are included in Insight Molecular Diagnostics's consensus?
The verified consensus includes 4 analysts.
How is Insight Molecular Diagnostics's target upside or downside calculated?
The average target of $8.25 is divided by the recorded price of $4.13, then one is subtracted to produce +99.8%. This does not guarantee a future return.
When was Insight Molecular Diagnostics's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.